This Week in Pediatrics — May 28, 2026

Welcome to This Week in Pediatrics. This week we're covering 8 notable papers spanning surgical decision-making, care for our most vulnerable infants, and the future of molecular medicine. Let's dive in.

Our first theme covers clinical crossroads in surgery and screening, beginning with a major trial in The New England Journal of Medicine that addresses a long-standing question in pediatric neurosurgery. [2] In children with Chiari type I malformation and syringomyelia, does adding a duraplasty to a posterior fossa decompression improve outcomes?

The Study This was a multicenter, cluster-randomized trial enrolling children 21 years or younger. Thirty-eight centers were randomized so that every patient at a given center received either posterior fossa decompression with duraplasty, or PFD-D, or posterior fossa decompression alone. The primary outcome was surgical complications within 6 months.

Results The investigators found no statistically significant difference in the primary outcome. The complication rate was 14% in the duraplasty group and 6% in the PFD-alone group. While this represents a more than two-fold increase in the odds of a complication, the result did not reach statistical significance, with a p-value of 0.11. When looking at secondary outcomes at 24 months, the picture becomes more complex. Clinical improvement was noted in 58% of the duraplasty group versus 46% of the PFD-alone group. Syrinx reduction was also substantially greater with duraplasty, at 3 millimeters versus 1.2 millimeters. Interestingly, the rate of repeat decompression was actually higher in the PFD-alone group, at 14% versus just 3% in the duraplasty group. Quality of life measures were similar between the two groups.

Conclusions The authors conclude that the rate of surgical complications did not differ significantly between the two procedures. The mixed secondary outcomes suggest that while duraplasty may offer better syrinx resolution, the overall benefits and risks remain unclear. This trial highlights the trade-offs involved, and the authors call for larger trials to provide a definitive answer.

From the operating room, we turn to the primary care clinic. A study in The Journal of Pediatrics explores how neighborhood factors influence behavioral health screening. [6] Investigators analyzed electronic health records from over 48,000 nine-year-old well-child visits, linking patient addresses to two different geospatial measures of neighborhood disadvantage: the Child Opportunity Index, or COI, and the Area Deprivation Index, or ADI.

Results The findings reveal a concerning disparity. Children living in the most disadvantaged neighborhoods had significantly lower odds of being screened for behavioral health concerns at their well visit. At the same time, these same children had significantly higher odds of screening positive on the Pediatric Symptom Checklist for total symptoms, externalizing problems, and attention problems. The two different disadvantage indices used, COI and ADI, were highly correlated and produced nearly identical results. This study underscores the critical importance of addressing structural barriers to equitable behavioral health screening and intervention efforts in pediatric primary care.

Our next section focuses on protecting our most vulnerable patients: neonates and infants. We begin with a systematic review and meta-analysis from the journal Pediatrics that quantifies the prevalence of brain abnormalities in children with congenital heart disease, or CHD. [5]

The Study Researchers analyzed 125 studies, synthesizing data on thousands of fetuses and children with isolated, non-syndromic CHD. They looked at structural cerebral abnormalities found on MRI at three key time points: the prenatal period, the postnatal-preoperative period, and the postoperative period.

Results The findings are sobering. The pooled overall prevalence of structural cerebral abnormalities was 23% in the prenatal period. This figure rose to nearly 37% in the postnatal-preoperative period, before any surgery had taken place. After surgery, the prevalence climbed to just over 50%. This step-wise increase highlights the cumulative burden of risk, suggesting that both the underlying condition and the subsequent surgical and postoperative care can have a significant impact on brain outcomes. This work reinforces the critical need for vigilant neuro-monitoring and neuro-protective strategies for this high-risk population.

Given these risks, a second paper in The Journal of Pediatrics offers a potential protective strategy. [7] It's a secondary analysis of a randomized trial looking at the impact of extended continuous positive airway pressure, or eCPAP, in stable preterm infants. The question was whether continuing CPAP for 14 days, even after infants were stable on room air, could reduce intermittent hypoxemia, a known risk factor for poor neurodevelopment.

Results The results were striking. Infants randomized to extended CPAP had significantly fewer intermittent hypoxemia episodes compared to those who discontinued CPAP. The eCPAP group experienced a mean of about 58 episodes per 24 hours, compared to over 150 in the discontinuation group. Extended CPAP was also associated with a higher mean oxygen saturation, despite no supplemental oxygen use, and a shorter cumulative duration of hypoxemic events. The authors propose that this simple, non-pharmacologic strategy could be a powerful tool to mitigate intermittent hypoxemia during a critical window of lung and brain development.

Finally, in this section, we look at necrotizing enterocolitis, or NEC. A pre-clinical study in Pediatric Research explores a potential preventative strategy using a 'NEC-in-a-Dish' model. [8] Researchers used enteroids derived from human neonatal intestinal tissue. They pretreated these cells with Urolithin A, a metabolite produced by gut microbes from dietary compounds, before exposing them to bacteria from an infant with NEC. The study found that Urolithin A pretreatment significantly decreased the expression of pro-inflammatory cytokines and enhanced the integrity of the epithelial barrier. Transcriptomic analysis showed it worked by downregulating key inflammatory pathways and upregulating antioxidant responses. While this is early, in-vitro work, it identifies Urolithin A as a promising candidate for dietary-based strategies to prevent NEC.

Our final theme this week is a glimpse into the future, with three papers highlighting molecular memory and targeted therapeutics. First, a paper in Nature reveals a fascinating and clinically relevant concept: human hematopoietic stem cells, or HSCs, remember inflammatory stress. [1] Researchers used xenograft models to show that after an inflammatory event, a distinct subset of HSCs emerges, which they term HSC inflammatory memory, or HSC-iM. These cells are more quiescent and have restrained output. This HSC-iM molecular program was found in HSCs from patients recovering from COVID-19, those with sickle cell disease, and in the context of aging. Most importantly, enrichment of this program in circulating blood cells was associated with a heightened risk score for all-cause mortality in human population cohorts, underscoring the clinical relevance of this fundamental discovery.

A powerful example of translating molecular understanding into therapy comes from Nature Medicine, which reports on a phase 2 trial for a rare pediatric cancer. [4] About 10 to 15 percent of gastrointestinal stromal tumors, or GISTs, are driven by functional loss of the succinate dehydrogenase complex, leading to an epigenetic change—genome-wide hypermethylation. This study tested rogaratinib, a pan-fibroblast growth factor receptor inhibitor, in 24 patients with these SDH-deficient GISTs. The results were impressive. The objective response rate was over 41%, with ten patients experiencing partial responses. The median progression-free survival was 31 months. This trial is a successful demonstration of a targeted cancer therapy based on an epigenetic mechanism of oncogene activation.

Finally, from Science Translational Medicine, we have a look at the next generation of gene editing. [3] A major challenge for CRISPR-based therapies is controlling the editing process to enhance safety. This paper introduces the PRINCE system, where both the nuclease protein and the guide RNA are inducible by small-molecule drugs. This allows for precise temporal control over gene editing. The compact version, named 'Little Prince,' was delivered via a single adeno-associated virus vector in mouse models. In a model of hypercholesterolemia, it led to average reductions of 45% in total cholesterol. Critically, the system showed a marked reduction in off-target activity compared to constitutive editors. This work positions PRINCE and Little Prince as controlled genome editing platforms with high potential for future in vivo therapeutic applications.

If you only have time for one paper this week, make it the study on extended CPAP in preterm infants by Mamidi and colleagues in The Journal of Pediatrics. [7] It's a highly practical paper describing a simple, non-pharmacologic intervention that was shown to significantly reduce intermittent hypoxemia, a key risk factor for poor outcomes in this vulnerable population.

Here are the key takeaways from this week in Pediatrics.

First, for children with Chiari I and syringomyelia, adding a duraplasty to posterior fossa decompression did not significantly increase complications and led to better syrinx reduction, but the overall risk-benefit balance remains unclear and awaits larger trials.

Second, children in disadvantaged neighborhoods are less likely to be screened for behavioral health concerns but more likely to screen positive, highlighting a critical need to address structural barriers to care.

Third, structural brain abnormalities are alarmingly common in children with congenital heart disease, with prevalence increasing from 23% prenatally to over 50% postoperatively, emphasizing the need for neuro-protective strategies across the entire care continuum.

Fourth, in stable preterm infants, extending CPAP therapy on room air is a simple, effective strategy to reduce the frequency and duration of intermittent hypoxemia.

And finally, the frontier of molecular medicine continues to advance, with new insights into inflammatory memory and promising results for targeted epigenetic cancer therapy and controllable in-vivo gene editing.

That's your roundup for This Week in Pediatrics. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.